The central regulator of adipogenesis, PPARc, is a nuclear receptor that is linked to obesity and metabolic diseases. Here we report that MKRN1 is an E3 ligase of PPARc that induces its ubiquitination, followed by proteasome-dependent degradation. Furthermore, we identified two lysine sites at 184 and 185 that appear to be targeted for ubiquitination by MKRN1. Stable overexpression of MKRN1 reduced PPARc protein levels and suppressed adipocyte differentiation in 3T3-L1 and C3H10T1/2 cells. In contrast, MKRN1 depletion stimulated adipocyte differentiation in these cells. Finally, MKRN1 knockout MEFs showed an increased capacity for adipocyte differentiation compared with wild-type MEFs, with a concomitant increase of PPARc and adipogenic markers. Together, these data indicate that MKRN1 is an elusive PPARc E3 ligase that targets PPARc for proteasomal degradation by ubiquitin-dependent pathways, and further depict MKRN1 as a novel target for diseases involving PPARc. Cell Death and Differentiation (2014) 21, 594-603; doi:10.1038/cdd.2013.181; published online 13 December 2013
Excessive body fat in obese individuals is considered a major cause of insulin resistance, cardiovascular diseases, and diabetes. 1 In obesity, adipocytes alter the status of energy homeostasis by the generation of adipokines, demonstrating that adipocytes have active roles in energy homeostasis and body composition, in addition to storage of triglycerides. 2 Adipokines secreted by obese adipocytes such as resistin and TNF-a impair insulin actions in peripheral tissues, whereas adiponectin from lean adipose tissue improves insulin sensitivity in liver and muscle. 2, 3 Therefore, a better understanding of adipocyte biology and mechanisms that direct adipocyte differentiation is being rapidly sought. 4 Adipocyte differentiation from pre-adipocytes is controlled by a number of transcriptional cascades, including peroxisome-proliferator-activated receptorg (PPARg), the CCAAT/ enhancer-binding protein (C/EBP) family, and adipocyte determination and differentiation-dependent factor. 5 Lossand gain-of-function studies have demonstrated that PPARg is a necessary and sufficient transcriptional regulator to convert adipocytes from their precursors. 6, 7 Activation of PPARg by its ligands induces PPARg binding to its responsive elements in the promoter, and increases the expressions of lipid synthesis-and differentiation-related genes, including CD36, lipoprotein lipase (LPL), fatty acid-binding protein (aP2), and C/EBPa. 8 Upstream transcriptional events that induce the expression of PPARg are C/EBPb, C/EBPd, Krox-20, KLF5, EBF, ZNF453, TCF7L2, and ADD1/SREBP1c transcription factors. 4, 5, 9 In contrast, inhibitory transcriptional regulators such as KLF2, GATA2/3, IRF, and b-catenin/TCF have been shown to suppress the expression of PPARg and adipocyte differentiation. 5, [9] [10] [11] [12] [13] PPARg protein is also post-translationally regulated by several modifications.
14 Phosphorylation on serine 122 in the AF1 region of PPARg is modified by ERK1/2 and P38/JNK kinases activated from growth factors, cytokines, and stress signals, and leads to inhibition of PPARg activity and adipocyte differentiation. 14, 15 Sumoylation on lysine residue 395 targets PPARg to NCoR corepressor and prevents repression of inflammatory genes. 16 A short-lived PPARg protein has been shown to be polyubiquitinated and degraded in a proteasome-dependent manner. 17, 18 Recent RNAi-based screening has shown that ubiquitin ligase Siah2 probably regulates PPARg coregulator (NCoR, RXRa), thereby inhibiting PPAR activity in mature 3T3-L1 adipocytes. 19 Another report also showed that ubiquitin ligase NEDD4-1 ubiquitinates PPARg protein. 20 These data indicate that various post-translational modifications are integral players responsible for the physiological effects of PPARg. Therefore, the identification and elucidation of the mechanisms of posttranslational modification will help us to understand the physiological functions of PPARg, adipocyte biology, and further applications to therapeutic interventions. Makorin Ring Finger Protein 1 (MKRN1) is known to act as an E3 ubiquitin ligase, targeting various substrates, such as hTERT, p53, and FADD. [21] [22] [23] [24] [25] It may also function as a regulator of nuclear receptors, including androgen and retinoic acid receptors, independent of E3 ligase activities. 26 In this study, we report that MKRN1 may mediate PPARg2 ubiquitination and proteasome-dependent degradation. The physiological function of MKRN1 in negative regulation of PPARg2 protein was further demonstrated using MKRN1 knockout MEFs, 3T3-L1, and C3H10T1/2 cell lines, indicating that MKRN1 is a potential new therapeutic target in PPARgrelated diseases.
Results
PPARc2 protein levels are regulated by MKRN1. In previous studies, MKRN1 was shown to repress the transcriptional activities of nuclear receptors such as androgen and retinoic acid receptors. 26 This finding prompted us to investigate whether MKRN1 also has regulatory effects on the transcriptional activities of PPARg, a nuclear receptor responsible for adipocyte differentiation. 27 The effects of MKRN1 on PPARg2 were examined by co-transfecting H1299 human lung cancer cells with plasmids expressing PPARg2 and PPRE-luciferase reporter in the presence or absence of troglitazone, an agonist of PPARg2. The expression of PPARg2 stimulated reporter gene expression, and this induction was further increased in the presence of troglitazone. Interestingly, MKRN1 co-expression with PPARg2 was able to suppress the transcriptional activities to basal levels, implicating a negative regulatory role of MKRN1 on PPARg2 activities (Supplementary Figure 1a) . To analyze the effects of MKRN1 more critically, we used MKRN1 depleted in H1299 followed by luciferase reporter assays. Two independent MKRN1 siRNA #5 and #6 (siMK1#5 and #6, respectively) suppressed levels of endogenous MKRN1 up to 90% in H1299 (Supplementary Figure 1b) . The data indicated that, under depletion of MKRN1, PPARg2 activities with or without troglitazone were doubled compared with those of the control siRNA (Supplementary Figure 1b) . To analyze the effects of MKRN1 on PPARg in a more physiological context, we employed a PC-3 human prostate cancer cell line, which endogenously expresses PPARg. 28 On ablation of MKRN1, we observed increased levels of PPARg protein levels, with no significant changes in mRNA levels ( Figure 1a) . Overall, these observations indicate that MKRN1 may negatively regulate PPARg in post-translation.
MKRN1 functions as an E3 ligase of PPARc. The ability of MKRN1 to regulate PPARg activities through post-translational regulation led us to examine the interactions between MKRN1 and PPARg2. Two proteins that are exogenously expressed in 293T cells interact with each other (Figure 1b,   Supplementary Figure 2a) . Interactions between endogenous PPARg and MKRN1 were further observed using extracts of PC-3 or 3T3-L1 cells differentiated into adipocytes by DMI (a cocktail of dexamethasone, 3-isobutyl-1-methylxanthine, and insulin) treatment (Figures 1c and d) . Finally, employing GST-pulldown assays using recombinant GSTPPARg2 and MKRN1 translated in vitro, we were able to show that the two proteins interact directly (Figure 1e) . Domain analyses using a truncated mutant of MKRN1 showed that the C-terminal region of MKRN1 was responsible for its interaction with PPARg2. On the other hand, N-terminal region of PPARg2 was required for its interaction with MKRN1 ( Supplementary Figures 2b and c) .
As MKRN1 is known as an E3 ligase, its ability to induce degradation of PPARg2 was tested. [21] [22] [23] [24] [25] With an increase of MKRN1 expressed in H1299 cells, the protein levels of PPARg2 decreased (Figure 2a ). Transient overexpression of MRKN1 in differentiated 3T3-L1 adipocytes suppressed the accumulation of endogenous PPARg, suggesting that MKRN1 induces PPARg destabilization. However, the addition of proteasome inhibitor reverted the destabilization of PPARg. As expected, MKRN1 E3 ligase-defective mutant H307E did not have significant effects on PPARg stability (Figure 2b ). Treatment with MG132, a proteasome inhibitor, blocked MKRN1-mediated degradation of PPARg2, indicating that proteasome-dependent degradation is required in these processes (Figure 2c ). When H307E, a MKRN1 E3 ligasedefective point mutant, was employed, it was able to bind to, but incapable of inducing degradation of, PPARg2, indicating that E3 ligase activities of MKRN1 are involved in the degradation mechanism (Figure 2d, Supplementary  Figure 3a) . Using cycloheximide (CHX), an inhibitor of protein translation, MKRN1 was shown to reduce the half-life of PPARg2 significantly, whereas H307E was not ( Supplementary  Figure 3b) . These observations suggest that the ablation of MKRN1 increased the stability and thus the half-life of endogenous PPARg protein in PC-3 cells (Supplementary Figure 3c) .
To further confirm the activities of MKRN1 on PPARg2, ubiquitination analyses were carried out under denaturation conditions. His-Ub pulldown assays using Ni 2 þ -NTA followed by immunoblotting of PPARg2 showed that there was an increase of PPARg2 ubiquitination in the presence of MKRN1 under treatment with MG132 (Figure 3a) . On the other hand, the H307E mutant was not able to induce ubiquitination, suggesting that the E3 ligase activities of MKRN1 are required for PPARg2 ubiquitination (Figure 3a) . The ubiquitination analyses were extended by first immunoprecipitating PPARg2, followed by immunoblotting to detect HA-Ub. These analyses also confirmed that only MKRN1 was able to induce PPARg2 ubiquitination, but not H307E (Figure 3b ). We detected residual amounts of ubiquitinated PPARg in the absence of MKRN1. Based on these data, we cannot exclude the possibility that other E3 ligases are involved in the ubiquitination of PPARg. 20 The levels of endogenous PPARg ubiquitinated were further detected using a whole-cell lysate of differentiated 3T3-L1. The results showed that in the presence of stably expressed MKRN1, there was an increase of ubiquitinated endogenous PPARg in differentiated 3T3-L1 cells, implicating MKRN1 as an E3 ligase of PPARg (Figure 3c) . Finally, using a cell-free Interaction between exogenous MKRN1 and PPARg2. HEK293T cells were transfected with the plasmids expressing 3 Â FLAG-PPARg2 (FLAG-PPARg2) and HA-MKRN1 plasmids with or without 10 mM MG132 for 6 h. The transfected cells were then harvested and WCE were immunoprecipitated using a-HA antibodies, followed by western blotting using a-FLAG and a-HA antibodies. Cell lysates (5% input) were used for western blotting. (c and d) Interactions between endogenous (endo) MKRN1 and PPARg. PC-3 cell lysates were immunoprecipitated using a-PPARg or a-IgG antibodies followed by western blotting using a-PPARg and a-MKRN1 antibodies. Cell lysates (2.5% input) were used for western blotting (c). WCE of 3T3-L1 undifferentiated or differentiated into adipocytes using DMI (dexamethasone þ 3-isobutyl-1-methylxanthine þ insulin) were immunoprecipitated using a-PPARg antibodies and detected as above. Cell lysates (2.5% input) were used for western blotting (d). (e) Direct interaction between PPARg2 and MKRN1 in vitro. In vitro translated MRKN1 was incubated with or without recombinant protein GST-PPARg2, followed by GST pulldown using glutathione-Sepharose. The proteins were detected using a-HA and a-PPARg antibodies. Input (5%) were used for western blotting ubiquitination assay system, MKRN1 was shown to induce ubiquitination of recombinant PPARg2, whereas MKRN1 H307E was not (Figure 3d ). GST was used as a control (Supplementary Figure 7a) . We observed a similar effect of MKRN1 on PPARg1 ubiqutination and degradation, suggesting that both PPARg1 and PPARg2 are substrates of MKRN1 ( Supplementary Figures 4a-c) .
Previous reports indicated that the presence of PPARg2 agonist expedites the degradation process of PPARg2. 17 To verify whether PPARg2 agonist facilitates MKRN1-dependent degradation processes, troglitazone was included in the assays. On treatment with troglitazone, there was an increase in MKRN1 and PPARg2 interaction, with more efficient MKRN1-dependent degradation of PPARg2 ( Supplementary  Figures 5a and b) . In agreement with these data, PPARg2 ubiquitination was further increased by the agonist (Supplementary Figure 5c) . Finally, using wild type or MKRN1 null MEFs, we showed that the presence of PPARg2 agonists such as rosiglitazone, troglitazone, or GW7845 stimulated PPARg2 destabilization in wild-type MEFs, whereas these effects were not clearly observed in MKRN1 knockout MEFs (Supplementary Figure 5d) . These results suggest that agonist-stimulated destabilization of PPARg2 requires the presence of MKRN1. These agonists did not affect MKRN1 levels, as shown in Supplementary Figure 5d . In summary, on interacting with PPARg, MKRN1 was able to induce the ubiquitination and degradation of PPARg, and these MKRN1-mediated processes were facilitated by the presence of a PPARg agonist.
Two lysines of PPARc located at the putative nucleus localization signal (NLS) are targeted for ubiquitination by MKRN1. PPARg is a nuclear receptor with a putative NLS region located between amino-acid regions 181 and 224. 29, 30 Figure 3 MKRN1 mediates ubiquitination of PPARg2 through E3 ligase activity. (a) Ubiquitination of PPARg2 by MKRN1 and MKRN1 H307E mutants. H1299 cells were transfected with the indicated plasmid in the presence or absence of MG132. His-Ub conjugated proteins were pulled-down using Ni 2 þ -NTA beads and detected using aPPARg or a-HA antibodies. (b) PPARg2 ubiquitination by active MKRN1 E3 ligase. H1299 cells, transfected as indicated, were immunoprecipitated with monoclonal a-PPARg antibodies, followed by western blotting as described above. (c) Ubiquitination of endogenous PPARg by MKRN1. 3T3-L1 stable cell lines expressing pBabe-Puro-MKRN1 (pBP-MK1) and pBabe-Puro-MKRN1 H307E (pBP-MK1 H307E) were differentiated by treatment with DMI. Cells were treated with MG132 for 6 h before harvest and lysed, followed by immunoprecipitation using a-ubiquitin antibodies and western blotting. (d) Ubiquitination of PPARg2 by MKRN1 in vitro. Purified recombinant GST-PPARg2 was incubated with E1, E2, ubiquitin (Ub) and ATP in the absence and presence of FLAG-MKRN1 wild-type or H307E mutant as indicated. Reactions were boiled in 1% SDS to disrupt protein interaction, followed by immunoprecipitation using a-PPARg antibodies. Ubiquitination of PPARg was analyzed by western blotting using a-Ub or a-PPARg antibodies. For input, ubiquitin reactions were directly subjected to western blotting using a-MKRN1 antibodies Our immunocytochemistry analyses showed that B80% of H1299 cells exhibited the nucleus-only localization of PPARg2, as previously reported (Supplementary Figure 6) . 31 Positively charged lysine sites in the NLS are commonly considered to have important roles in the nuclear localization of various proteins. [29] [30] [31] [32] When two lysines that are consecutively located at 184 and 185 sites in the NLS region were mutated to alanines (2KA), B30% of the cells showed nuclear localization of PPARg2, whereas the rest displayed nuclear/ cytosol localization (Supplementary Figure 6) . However, when the two lysines were mutated to arginines (2KR), no significant changes of PPARg2 localization were observed (Supplementary Figure 6) . On co-expression of MKRN1 and PPARg2 or 2KR, we observed the nuclear/cytoplasmic localization of PPARg2 in 70% of cells expressing both proteins (Supplementary Figure 6) . These observations suggest that MKRN1 might mask the NLS function of PPARg2 in a way that blocks its localization into the nucleus. As expected, 2KA was able to bind to MKRN1 as the wild type ( Figure 4a ). One interesting observation was that this protein was protected from MKRN1-mediated ubiquitination and degradation, indicating that these two lysines might be targeted for ubiquitination by MKRN1 (Figures 4b-d) . Overall, MKRN1-mediated ubiquitination of PPARg2 at lysines 184 and 185 located at NLS may be necessary for its ubiquitination and subsequent degradation (Figure 4e) . A cell-free ubiquitination system was employed to further confirm whether lysines 184 and 185 are actually targeted for ubiquitination by MKRN1. The 2KA mutant was not ubiquitinated by MKRN1, suggesting that these two sites are indeed targeted for ubiquitination (Supplementary Figure 7b) . As MKRN1 was able to induce translocation of both wild-type PPARg2 and 2KR mutants into the cytoplasm, interaction between the two proteins seems to be required for translocation of PPARg by MKRN1, rather than the ubiquitination process.
MKRN1 suppresses adipocyte differentiation. As the forced expression of PPARg in fibroblastic cells can induce adipogenesis, we investigated the physiological effects of MKRN1 in adipocyte differentiation. The role of MKRN1 as a negative regulator of PPARg was analyzed by adipocyte differentiation from 3T3-L1 pre-adipocytes stably overexpressing MKRN1 or H307E. Overexpression of MKRN1 using a retrovirus suppressed the adipogenesis of 3T3-L1 induced by DMI treatment, as assessed using Oil-Red-O staining and morphological analysis (Figure 5a and Supplementary Figure 8a) . Overexpressed MKRN1 consistently suppressed the expressions of adipogenic markers, such as aP2, C/EBPa, and CD36, as well as PPARg (Figures 5b and c) . Overexpressed H307E did not exhibit any noticeable effects on adipogenes, which corroborates the data shown above (Figures 5a-c and Supplementary Figure 8a) . To further confirm whether overexpressed MKRN1 could Figure 4 Two lysine residues of PPARg2 (184 and 185) are targeted for ubiquitination by MKRN1. (a) Interaction between PPARg2 point mutant (2KA) and MKRN1. HEK293 T cells were transfected with the plasmids expressing PPARg2 WT and PPARg2 2KA mutant alone or with HA-MKRN1. WCE were immunoprecipitated with a-HA antibodies followed by western blotting using a-HA or a-PPARg antibodies. Cell lysates (5% input) were used for western blotting. (b) Effects of MKRN1 on protein stability of PPARg2 2KA mutant. H1299 cells transfected with plasmids expressing the indicated proteins were detected by western blotting, as indicated above (Figure 2a) . (c) Half-life of PPARg2 2KA mutant in the presence of MKRN1. H1299 cells were transfected with plasmids expressing indicated proteins followed by treatment with 50 mg/ml CHX for up to 60 min. WCE were perceived by western blotting and their levels measured as in Supplementary Figure 3b. (d) PPARg2 2KA ubiquitination by MKRN1. H1299 cells were transfected with the plasmids expressing MKRN1, PPARg2, PPARg2 2KA, or HA-Ub. WCE were immunoprecipitated with monoclonal a-PPARg antibodies, followed by western blotting, as described in Figure 3b . (e) Schematic of PPARg2 ubiquitination target sites suppress adipocyte differentiation by specifically targeting PPARg for destabilization, we performed rescue experiments by expressing PPARg in the presence of MKRN1. We observed that overexpression of PPARg was able to overcome MKRN1-dependent suppression of adipocyte differentiation, suggesting that MKRN1 could target PPARg as its substrate ( Figure 6 ). The effects of MKRN1 on adipocyte differentiation were further confirmed under MKRN1-depleted conditions. To maximize the effects of MKRN1 depletion using shMKRN1 #1 and #3 on adipocyte differentiation, we applied DI instead of DMI, which is known to induce less-efficient adipocyte differentiation. 33, 34 In both stable cell lines, we were able to observe effective differentiation of pre-adipocytes with greater expressions of PPARg, aP2, and its other targets (Figures 5d and e and  Supplementary Figure 8b) . Consistently, the real-time reverse-transcription PCR (qRT-PCR) data indicated that the adipogenic markers, including PPARg, aP2, and CD36, were all increased under MKRN1 depletion (Figure 5f ). The effects of MKRN1 on adipocyte differentiation were also observed in mesenchymal C3H10T1/2 cells. MKRN1 or pBabe empty vector was stably overexpressed and stimulated into adipocytes with the addition of DMI and PPARg agonists, GW7845. Consistent with the effects in 3T3-L1 cells, C3H10T1/2 cells stably expressing MKRN1 decreased PPARg protein expression, resulting in less lipid accumulation compared with control cells (Supplementary Figures 9a  and b) . Gene expression analyses also showed decreased expression of PPARg and its target aP2 mRNA in cells stably expressing MKRN1 (Supplementary Figure 9c) . To address the roles of endogenous MKRN1 in C3H10T1/2 cells, stable cells expressing shMKRN1 #3 or GFP were generated. Compared with control cells, stable C3H10T1/2 cells expressing shMKRN1 #3 exhibited markedly increased lipid accumulation and expression of adipocyte markers (Supplementary Figures 10a-c) . . Stable cell lines constitutively depleted of MKNR1 were constructed using a lentivirus expressing shRNA for GFP or mouse MKRN1 (shGFP, shMKRN1 #1, shMKRN1 #3, respectively). The adipogeneses of these three cell lines were induced using DI (dexamethasone þ insulin) for 6 days. Cells were stained and detected as described above. (e) MKRN1 knockdown increases the levels of adipogenic proteins. WCE from above were analyzed as above. (f) Effects of MKRN1 depletion on mRNA levels of the adipogenic markers. The mRNA of adipogenic markers were analyzed as described above. Data are presented mean±S.D.; n ¼ 3 with *Po0.05, **Po0.01 and ***Po0.001 compared with each lane
To further confirm the effects of MKRN1 in adipogenesis shown above, potentials of MKRN1 knockout or wild-type MEFs for adipocyte differentiation were compared. Similar to the increased differentiation in MKRN1-silenced 3T3-L1 and C3H10T1/2 cells, primary MKRN1 À / À MEFs showed robust increases in lipid accumulation and morphological differentiation when compared with WT MEFs (Figures 7a-c ). There were also significant increases in protein and mRNA levels of PPARg, aP2, C/EBPa, and CD36 in the MKRN1 À / À cells (Figures 7d and e) . As expected, the expressions of C/EBPb and C/EBPd were not affected in the MKRN1 À / À cells, suggesting that there are PPARg-specific effects of MKRN1 in adipogenesis (Figures 7d and e) . Confirming these observations, the ubiquitination status of endogenous PPARg was weaker under MKRN1 À / À MEFs, suggesting that MKRN1 is necessary for PPARg ubiquitination (Figure 7f) . Overall, our data demonstrate that MKRN1 can negatively control adipocyte differentiation by suppressing PPARg function posttranslationally.
Discussion
The combined trends of increased caloric intake and decreased physical exercise have contributed to the increasing prevalence of obesity and related insulin resistance in industrialized populations. Insulin resistance is associated with increased risks of type 2 diabetes and cardiovascular disease. At the crossroads of obesity, insulin resistance, and cardiovascular disease lies the nuclear receptor PPARg. [35] [36] [37] [38] Therefore, better understanding of PPAR biology is of scientific and therapeutic importance.
As PPARg functions as a master regulator of adipogenesis and is a critical factor associated with various metabolic diseases, amounts of PPARg should be tightly controlled at the transcriptional and post-translational levels. 5, 8, 35 Transcriptional pathways that control the expression of PPARg have been extensively studied; 7, 16 but the stability of short-lived PPARg, which is probably controlled by post-translational modification, remains incompletely understood. Previous studies showed that PPARg is polyubiquitinated and degraded in a proteasome-dependent manner. 17 Ubiquitin ligase Siah2 was recently identified for its inhibitory actions on PPARg activity, further suggesting that ubiquitin ligase is an important regulator of PPARg activity and adipogenesis. However, Siah2 does not appear to directly interact with PPARg, but instead a nuclear receptor corepressor, NCoR, has been suggested as a target of Siah2, indicating that another E3 ligase(s) exists for ubiquitination of PPARg. 19 In this study, we propose MKRN1 as a direct E3 ligasetargeting PPARg. MKRN1 reduces PPARg protein levels through direct interaction. Two lysine residues at 184 and 185 in the DNA-binding domain of PPARg are critical sites for MKRN1-mediated ubiquitination. Interestingly, these two lysine residues are conserved in mammals, birds, reptiles, amphibians, and fishes, implying an evolutionarily conserved role for MKRN1 in PPARg regulation. Overexpression and knockdown studies indicate that MKRN1 is a negative regulator of PPARg, decreasing PPARg protein levels. MEFs isolated from MKRN1 À / À embryos further demonstrate the regulatory roles of MKRN1 in PPARg-mediated adipogenesis. Thus, our results demonstrate that MKRN1 is a novel Previous studies have implicated that an elusive E3 ligase responsible for PPARg degradation is tightly linked to PPARg activation on ligand binding. 17 Therefore, we investigated whether the regulatory actions of MKRN1 could be affected by PPARg activation. The regulatory activities of MKRN1 on PPARg appear to be influenced by ligand binding, as treatment with troglitazone enhanced the association between the two proteins and increased the ubiquitination of PPARg, confirming previous findings (Supplementary Figures  5a-d) . 17, 19 How does PPARg activation by agonists facilitate MKRN1 and PPARg interaction and subsequently increase the degradation of PPARg? One may speculate that the activation of PPARg causes a conformational shift toward the higher incidence of MKRN1 binding with PPARg, followed by cytoplasmic relocation and degradation. How the regulatory functions of MKRN1 act on PPARg in a ligand-dependent manner remains an intriguing question for future studies.
In this study, we identified the functions of MKRN1 in posttranslational modification of PPARg and adipocyte differentiation. Interestingly, however, MKRN1 is expressed in multiple tissues, suggesting functions in other cell types. Whether MKRN1 leads to the suppression of PPARg in non-adipose tissues and similar modulations of other nuclear receptor families associated with metabolic disease are intriguing questions. Further studies are necessary to evaluate the effects of MKRN1 in non-adipose tissues and other targets for degradation.
Our results also suggest that MKRN1 could be a novel therapeutic target for obesity and diabetes. Further studies of MKRN1 activities and cellular and pathological effects in vivo are of great importance for finding novel therapeutic and KO #2) and wild-type MEFs, cultured in medium containing DMI and troglitazone from 0 to 14 days, were photographed as described above (a). Differentiated MEF cells were detected using Oil-Red-O staining (b). (c) The Oil-Red-O dye was extracted using isopropanol and measured at 500 nm. Data represent mean±S.D.; n ¼ 3 with ***Po0.001. See Materials and methods for details. (d) Protein levels of PPARg and its target proteins in wild type and MKRN1 knockout MEFs. MKRN1 knockout MEFs displayed increased levels of PPARg with its target proteins. WCE of MKRN1 knockout and wild-type MEFs were analyzed as described in Figure 5b . (e) mRNA levels of PPARg and its target proteins in wild type and MKRN1 knockout MEFs. MKRN1 knockout MEFs increase in mRNA levels of the adipogenic markers. The mRNA of adipogenic markers and upstream of PPARg were analyzed by qRT-PCR analysis as described in Figure 5c . Data are mean±S.D.; n ¼ 3 with ***Po0.001 compared with each lane. (f) Reduction of endogenous PPARg ubiquitinationin MKRN1 knockout MEFs. MKRN1 WT and knockout MEFs were differentiated to adipocytes using DMI and troglitazone (DMI þ tro) for 14 days. Subsequently, WT and knockout MEFs were treated with 10 mM MG132 (MG) for 6 h before harvest and lysed, followed by immunoprecipitation using a-PPARg antibodies and western blotting under denaturating conditions approaches to obesity-related diseases. The generation and characterization of tissue-specific knockout mice will be required to determine the roles of MKRN1 in obesity and related metabolic diseases. It will be interesting to explore whether MKRN1 and its mechanisms can be exploited to develop new therapeutic interventions for the treatment of obesity and metabolic diseases in the future.
Materials and Methods Plasmids. pcDNA3.1-PPARg2 was generated from pBabe-puro-PPARg2, which was described previously. 34 pcDNA3.1-PPARg2 2KA and pcDNA3. 1-PPARg2 2KR mutants were produced using site-directed mutagenesis methods, as provided by the manufacturer (Takara Bio, Shiga, Japan). The primers used for these constructs are as follows:
(reverse). MKRN1 constructs (pcDNA3-HA-MKRN1 WT/H307E, pcDNA3.1-MKRN1 WT/H307E, pcDNA3-FLAG-MKRN1 WT/H307E) were described previously.
22 pcDNA3-HA-MKRN1 WT and H307E mutant were subcloned into pBabe-Puro. pcDNA3-His-Ub and pHM6-HA-Ub was previously described. 39, 40 pTK-PPREx3-luc was kindly provided by HW Lee (Yonsei University, Seoul, Korea).
Antibodies and chemicals. Western blotting and immunoprecipitation data analysis were performed using the following antibodies: PPARg (mouse sc-7273X, rabbit sc-7196X, Santa Cruz Biotechnology, Santa Cruz, CA, USA), C/EBPa (rabbit sc-61X, Santa Cruz Biotechnology), C/EBPb (rabbit sc-150X, Santa Cruz Biotechnology), C/EBPd (rabbit sc-636X, Santa Cruz Biotechnology), aP2 (goat sc-18661, Santa Cruz Biotechnology), HA (mouse sc-7392, rabbit sc-805, Santa Cruz Biotechnology), FLAG (mouse F3165, rabbit F7425; Sigma-Aldrich, St. Louis, MO, USA), GFP (sc-8334, Santa Cruz Biotechnology), b-actin (A5316; Sigma-Aldrich), normal mouse IgG (sc-2025; Santa Cruz Biotechnology), normal goat IgG (sc-2028; Santa Cruz Biotechnology), myc (sc-40, Santa Cruz Biotechnology), MKRN1 (A300-990A; Bethyl Laboratories, Montgomery, AL, USA), and HRPconjugated-a-UbFK2 (PW0150, Enzo Life Sciences, Farmingdale, NY, USA). CHX (C4859), N-ethylmaleimide (NEM, E3876) and dimethyl sulfoxide (DMSO, D8418), dexamethasone (D1756), IBMX (I5879), Troglitazone (T2573), Rosiglitzaone (R2408), and Oil-Red-O (O0625) were purchased from Sigma-Aldrich. Insulin (11 376 497 001) was purchased from Roche (Mannheim, Germany). GW7845 was kindly provided by T Willson (GlaxoSmithKline, QC, Canada).
Transfection. H1299 and PC-3 cells were transfected using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Polyethyleneimine (PEI, Sigma-Aldrich) was used for the transfection of HEK293T cells. 3T3-L1 cells were transfected using a microporator (Neon Transfection System, Invitrogen). Lipofectamin RNAiMax (Invitrogen) was used for siRNA transfection. MKRN1 siRNAs were previously described (the siRNA sequences are as follows: #5-5 0 GGCGAAGCTGAGTCAAGAA-3 0 and #6-5 0 -GGATCCTCTCC AACTGCAA-3 0 ).
22
Cell culture and adipocyte differentiation. H1299 (human lung carcinoma cell line) and HEK293T (human kidney cancer cell line) were cultured in DMEM containing 10% FBS (Gibco, Invitrogen). Adipocytes were differentiated from 3T3-L1 pre-adipocyte cells, mesenchymal C3H10T1/2 cells, or mouse MEFs. Briefly, 3T3-L1 cells were maintained in DMEM with 10% bovine serum for 3-5 days, and confluent cells differentiated in DMEM containing 10% FBS, dexamethasone (1 mM), 3-isobutyl-1-methylxanthine (IBMX; 520 mM), and insulin (1 mg/ml) (DMI mixture) for 2 days. The cells were then cultured in DMEM containing 10% FBS and insulin (5 mg/ml) for 2 additional days. MEFs and C3H10T1/2 cells were cultured in DMEM with 10% FBS for 3-5 days, and confluent cells differentiated in DMEM containing 10% FBS, dexamethasone (1 mM), 3-isobutyl-1-methylxanthine (IBMX; 520 mM), insulin (10 mg/ml; (DMI mixture) and TZD (1 mM, Troglitazone and GW9544) for 2-3 days. The cells were further cultured in DMEM containing 10% FBS, insulin (10 mg/ml), and TZD (1 mM) for an additional 6-8 days. Differentiated cells were detected using Oil-Red-O staining, as previously described (O0625, Sigma-Aldrich). 41 The stained cells were photographed using CKX41SF (Olympus, Tokyo, Japan). The dye from Oil-Red-O staining were extracted using isopropanol, followed by optical density measurement at 500 nm using Benchmark Plus (Bio-Rad Inc., US).
Generation of primary MEFs. MKRN1 knockout MEFs were generated as previously described using MKRN1 C57BL/6J mice. 25 Briefly, at E13.5 day, embryos were removed from pregnant female mice and ground using blades. Ground embryos were incubated in 3 ml of trypsin-EDTA 37 1C for 20 min, transferred to 150-mm culture dishes, and incubated at 37 1C in 20 ml of complete media. After 8 h, the medium was changed to fresh DMEM containing 10% FBS. Once the cells were 70-80% confluent, they were maintained at 1 : 3 ratios.
Generation of MKRN1 overexpression and knockdown stable cell lines. All short-hairpin RNA (shRNA) constructs were purchased from Sigma-Aldrich. The sequences are as follows: mouse MKRN1#1-5
0 -GAGTGGGACTTGTTTCACGAT-3 0 . 3T3-L1 cells stably expressing control shRNA (shGFP) or mouse MKRN1 shRNA (shMKRN1#1, shMKRN1#3) were established using the manufacturer's instructions. HEK293T cells were transfected with pLKO.1-shGFP or shMKRN1#1, #3, and lentiviral packaging vectors. At 48 h post transfection, viral supernatants were harvested, filtrated, and added to 3T3-L1 or C3H10T1/2 cells. Transduced cells were selected by puromycin treatment for 7 days. MKRN1 overexpression cell lines were produced using pBABE-puro-MKRN1 and pBABE-puro-MKRN1 H307E mutant plasmids, and the packaging cell line Phoenix E, as previously described. 34 In vitro ubiquitination assay. FLAG-MKRN1 was transiently expressed in HEK293T cells, purified by immunoprecipitation using anti-FLAG M2 affinity gel (Sigma-Aldrich, A2220), and eluted by adding FLAG peptide (Sigma-Aldrich, F3290) according to the manufacturer's instructions. Bacterially expressed recombinant GST-PPAR2 was incubated with 200 ng E1 (UBE1, E-305, Boston Biochem, Cambridge, MA, USA), 500 ng E2 (UbcH5c, Boston Biochem, E2-627), 10 mg Ubiquitin (Sigma-Aldrich, U6235), 2 mM ATP (Fermentas, Vilnius, Lithuania, R0441) in the absence and presence of FLAG-MKRN1 wild type or H307E mutant in 50 ml of reaction buffer (40 mM Tris-HCl, pH 7.6, 50 mM NaCl, and 1 mM DTT) for 3 h at 37 1C. After incubation, reactions were boiled in 1% SDS to disrupt any protein interactions, diluted with immunoprecipitation buffer to 0.1% SDS, and immunoprecipitated using a-PPARg mouse monoclonal antibodies (Sigma-Aldrich, 7273X), followed by western blotting using a-Ub-HRP or a-PPARg mouse antibodies (Sigma-Aldrich, 7273X). Reactions were directly subjected to western blotting using a-MKRN1 antibodies to see MKRN1 self-ubiquitination as a control.
RT-PCR analysis. RNAs were extracted using Trizol (Invitrogen) according to the manufacturer's directions. cDNA was synthesized from total RNA using Reverse Transcriptase M-MLV (Takara Bio), amplified, and then analyzed using the QuantiTect SYBR Green PCR Kit and real-time PCR (Qiagen) with the following primers: human and mouse MKRN1; (forward), 5 0 -GGCTGGGCAGTTTTTGAA-3 0 (reverse). Each gene expression level was normalized to that of the 36B4 gene in the same sample, except for those shown in Figure 1a . The qRT-PCR data shown in Figure 1a were normalized by the GAPDH gene.
Immunoprecipitation and ubiquitination assay. HEK293T cells were lysed using lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, and a protease inhibitor cocktail (2 mg/ml Aprotinin, 1 mg/ml Pepstatin A, 2 mg/ml Leupeptins, 100 mg/ml PMSF (phenylmethanesulfonylfuoride), Sigma-Aldrich). Cell lysates were incubated with antibodies for 2 h, followed by incubation with protein G Sepharose (GE Healthcare, UK) for 2 h. Immunoprecipitates were boiled in sample buffer for 5 min. In the ubiquitination assay using HA-Ub, H1299 or 3T3-L1 cells transfected with
